Rolvedon™ (eflapegrastim-xnst) injection has been approved to decrease the incidence of chemotherapy-induced febrile neutropenia in adult patients.

• Manufactured by Spectrum Pharmaceuticals, Inc., Rolvedon™ injection is a long-acting granulocyte colony-stimulating factor (G-CSF) with a novel Spectrum has received an indication to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia.
• Rolvedon is contraindicated in patients with a history of serious allergic reactions to eflapegrastim, pegfilgrastim or filgrastim Reactions may include anaphylaxis.
• It is expected to be available in fourth quarter 2022.